TARA-002

Protara Therapeutics' TARA-002 demonstrates strong efficacy in Phase 2 ADVANCED-2 trial for non-muscle invasive bladder cancer, achieving 72% six-month complete response rate across all BCG exposure levels.

Protara Therapeutics anticipates mid-2025 data from the ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC) patients, building on positive six-month results.

Protara Therapeutics' TARA-002 demonstrated a 72% complete response rate in non-muscle invasive bladder cancer patients, regardless of prior BCG exposure.

Protara Therapeutics' TARA-002 achieved an 80% complete response rate (CRR) in non-muscle invasive bladder cancer (NMIBC) patients.

Protara Therapeutics' TARA-002 demonstrated a 72% six-month complete response rate in NMIBC patients across various BCG exposure statuses.